scispace - formally typeset
D

David J. Hosking

Researcher at University of Nottingham

Publications -  134
Citations -  10711

David J. Hosking is an academic researcher from University of Nottingham. The author has contributed to research in topics: Osteoporosis & Bone remodeling. The author has an hindex of 48, co-authored 134 publications receiving 10354 citations. Previous affiliations of David J. Hosking include University of Texas Health Science Center at San Antonio & Nottingham City Hospital.

Papers
More filters
Journal ArticleDOI

Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget’s disease

M. Hooper, +9 more
- 01 Jan 2009 - 
TL;DR: Although ALN 280 mg OW OBS was similarly effective as ALN 40 mg/day in reducing total ALP in patients with Paget’s disease of bone, the alendronate 40-mg-a-day tablet appeared to be better tolerated in this study.
Journal ArticleDOI

Update on calcium and vitamin D metabolism

Opinder Sahota, +1 more
- 01 Jan 1999 - 
TL;DR: The regulation of extracellular calcium involves the co-ordinated actions of the parathyroid hormone vitamin D endocrine axis acting on the gut, kidney and bone, which maintains the concentration gradient for intracellular calcium, important in the regulation of a variety of cellular functions.
Journal ArticleDOI

Oral antiresorptive therapy

Ira Pande, +1 more
- 01 Feb 2005 - 
TL;DR: The effects and potential future role of newer agents such as ibandronate and the innovative, yet disappointing results from combining an antiresorptive agent (alendronate) with the anabolic effects of teriparatide are discussed.
Journal ArticleDOI

The diphosphonate space: a useful quantitative index of disease activity in patients undergoing hexamethylene diphosphonate (HMDP) bone imaging for Paget's disease

Andrew Evans, +4 more
- 01 Jan 1991 - 
TL;DR: In a series of 49 patients with Paget's disease the diphosphonate space (DPS) correlated well with other indicators of disease activity such as alkaline phosphatase and urinary hydroxyproline levels and provides a sensitive indicator of response to treatment with intravenously administered bisphosphonates.
Journal ArticleDOI

Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis.

Alan C. Perkins, +8 more
- 27 Mar 2006 - 
TL;DR: It is demonstrated that even when taken with a minimal volume of water the esophageal transit and gastric emptying of the film-coated 35 mg weekly risedronate placebo tablet was similar in kyphotic subjects to previously obtained results from healthy control subjects.